Advanced Prostate Cancer: Enhancing Combination Therapy

Discover considerations for doublet or triplet therapy in advanced prostate cancer, analyzing the benefits and manageable added toxicity, as discussed by renowned experts in the field.

EP: 1.Optimizing Prostate Cancer Care: A Collaborative Approach

EP: 2.Choosing Partners in Cancer Care: A Strategic Approach

EP: 3.Early-Stage Prostate Cancer Screening and Management Trends

EP: 4.Navigating Prostate Cancer Progression: Risk Assessment and Management

EP: 5.Prostate Cancer Hormone Therapies: A Comprehensive Overview

EP: 6.Enhancing Efficacy in Advanced Hormone-Sensitive Prostate Cancer Treatment

Now Viewing

EP: 7.Advanced Prostate Cancer: Enhancing Combination Therapy

EP: 8.Overcoming Barriers to Triplet Therapy in Prostate Cancer

EP: 9.Advanced Prostate Cancer: Patient Care Continuity

EP: 10.Optimizing Care Collaboration in Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

December 3rd 2024

JANX007 demonstrates encouraging clinical activity in mCRPC

Hannah Clarke

Data showed that all patients achieved a PSA decline of at least 50%.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 2nd 2024

Ralph Miller, MD, on the state of HIFU in prostate cancer

Ralph J. Miller Jr, MD

"Most of the published data about HIFU tended to be with relatively short-term follow-up," says Ralph J. Miller Jr, MD.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

November 25th 2024

Capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC

Hannah Clarke

Data from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.

November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke

In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.

Related Content

Advertisement

December 3rd 2024

JANX007 demonstrates encouraging clinical activity in mCRPC

Hannah Clarke

Data showed that all patients achieved a PSA decline of at least 50%.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 2nd 2024

Ralph Miller, MD, on the state of HIFU in prostate cancer

Ralph J. Miller Jr, MD

"Most of the published data about HIFU tended to be with relatively short-term follow-up," says Ralph J. Miller Jr, MD.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

November 25th 2024

Capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC

Hannah Clarke

Data from the CAPItello-281 trial also showed a trend toward an improvement in overall survival.

November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke

In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.